Imagine a world where groundbreaking treatments for rare diseases, life-threatening infections, and chronic conditions are on the brink of approval. But here's where it gets controversial: which of these potential lifesavers will make it to patients in need, and who gets to decide? This was the core dilemma faced at the Advisory Committee on Medicines (ACM) Meeting 54, held on 4-5 December 2025, where experts meticulously evaluated 10 premarket registration applications submitted to the Therapeutic Goods Administration (TGA).
Applications for New Medicines (Type A):
The committee assessed four applications for entirely new medicines, each containing novel active substances not yet approved in Australia. These included:
- Apadamtase alfa / Cinaxadamtase alfa (ADZYNMA) by Takeda Pharmaceuticals, targeting the rare and life-threatening condition congenital thrombotic thrombocytopenic purpura. This application was designated as an orphan drug, highlighting its potential impact on a small but vulnerable patient population.
- Cefiderocol sulfate tosilate (FETROJA) by Accelagen, an antibiotic designed for adults with limited treatment options, addressing the growing crisis of antibiotic resistance.
- Seladelpar lysine dihydrate (LIVDELZI) by Gilead Sciences, aimed at treating primary biliary cholangitis in adults, a chronic liver disease with few effective therapies.
Applications for New Indications (Type C):
Six applications sought to expand the use of already approved medicines to new therapeutic areas, including:
- Darolutamide (NUBEQA) by Bayer, proposed for metastatic hormone-sensitive prostate cancer, a significant advancement in oncology.
- Pembrolizumab (KEYTRUDA) by Merck Sharp & Dohme, targeting head and neck squamous cell carcinoma, a challenging cancer with high unmet need.
- Lenacapavir sodium (YEYTUO) by Gilead Sciences, for HIV pre-exposure prophylaxis in adults, a priority application given its potential to prevent new infections.
- Buprenorphine (SUBLOCADE) by Indivior, a modified-release injection for opioid dependence, offering a novel approach to addiction treatment.
- Guselkumab (TREMFYA) by Janssen-Cilag, for moderate to severe plaque psoriasis in children aged 6 and older, addressing a gap in pediatric dermatology.
- Acalabrutinib maleate monohydrate (CALQUENCE) by AstraZeneca, for chronic lymphocytic leukemia and small lymphocytic lymphoma, providing a targeted therapy option.
- Iptacopan (FABHALTA) by Novartis, for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy in adults, with both orphan and priority designations.
And this is the part most people miss: the committee also advised on a nomination for the Medicines Repurposing Program, which explores new uses for existing drugs, and a general request for monitoring requirements for an approved medicine. These discussions, along with detailed advice, may be published in the Australian Public Assessment Reports (AusPARs), available for public review.
Post-Market Considerations:
Interestingly, the ACM was not asked to provide advice on any post-market or safety issues during this meeting, a rare occurrence that underscores the focus on premarket evaluations.
A Thought-Provoking Question: As these applications move closer to approval, how do we balance the urgency of patient need with the rigor of scientific evaluation? Should certain conditions, like rare diseases, receive expedited approval processes, or does this compromise safety standards? We’d love to hear your thoughts in the comments below.
For more information on the ACM and its work, visit their official page or contact the ACM Secretary directly. The future of medicine is being shaped here—and your perspective matters.
